- Conditions
- Cardiac Amyloidosis
- Interventions
- 18F-Florbetaben (Neuraceq®) PET/MRI
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 85
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Transthyretin Gene Mutations, Transthyretin Amyloidosis
- Interventions
- None. Observational Study.
- Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
- Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Interventions
- Vutrisiran, Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 655 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 17
- States / cities
- La Mesa, California • Los Angeles, California • Stanford, California + 13 more
- Conditions
- Cardiac Amyloidosis
- Interventions
- F-18 florbetapir
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Amyloidosis Cardiac
- Interventions
- Sonotherapy
- Combination Product
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Amyloidosis, Hereditary, Transthyretin Amyloidosis
- Interventions
- Patisiran, Vutrisiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 15
- States / cities
- La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 12 more
- Conditions
- Amyloidosis, Amyloid, Amyloid Neuropathies, Familial, Amyloid Cardiomyopathy, Amyloid - Primary, Transthyretin Amyloidosis, AL Amyloidosis
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Interventions
- NTLA-2001, Placebo
- Biological · Drug
- Lead sponsor
- Intellia Therapeutics
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more
- Conditions
- Amyloid Cardiomyopathy, Transthyretin-Related
- Interventions
- Acoramidis (AG10)
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more
- Conditions
- FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
- Interventions
- Inotersen, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 9
- States / cities
- Orange, California • Indianapolis, Indiana • Baltimore, Maryland + 5 more
- Conditions
- Cardiomyopathies, Primary
- Interventions
- (18F)Flutemetamol
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Amyloid Cardiomyopathy, Transthyretin-Related
- Interventions
- AG10 oral tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Amyloid, Amyloidosis, Spinal Stenosis, Transthyretin Amyloidosis, Primary Amyloidosis of Light Chain Type
- Interventions
- Biopsy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 200 participants
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Amyloidosis; Systemic
- Interventions
- 124I-AT03
- Drug
- Lead sponsor
- Attralus, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
- Interventions
- Treatment of transthyretin (ATTR) amyloidosis in observational study setting
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 30
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 22 more
- Conditions
- Aortic Stenosis, Transthyretin Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
- Interventions
- 99mTc-PYP
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
- Interventions
- Not listed
- Lead sponsor
- eMyosound SAS
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Cardiac Amyloidosis
- Interventions
- AI ECG Amyloid algorithm
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more
- Conditions
- Transthyretin-associated Amyloidosis With Polyneuropathy
- Interventions
- Fx-1006A
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hereditary Amyloidosis, Transthyretin-Related
- Interventions
- neurofilament light chain, In-vivo Meissner Corpuscle imaging, Nerve conduction study
- Diagnostic Test
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 30 Years to 90 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cardiac Amyloidosis
- Interventions
- EchoNet-LVH Assessment
- Diagnostic Test
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Palo Alto, California • Chicago, Illinois + 1 more
- Conditions
- Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
- Interventions
- tafamidis
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Interventions
- Placebo, Patisiran
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more